Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer

Corral-Jaime, J. (Jesús); Mok, T.S. (Tony S.); Nakagawa, K. (Kazuhiko); Rosell, R. (Rafael); Lee, K.H. (Ki Hyeong); Migliorino, M.R. (Maria Rita); Pluzanski, A. (Adam); Linke, R. (Rolf); Devgan, G. (Geeta); Tan, W. (Weiwei); Quinn, S. (Susan); Wang, T. (Tao); Wu, Y.L. (Yi-Long)

Keywords:

Materias Investigacion::Ciencias de la Salud::Oncología
EGFR
NSCLC
Dacomitinib
Dose
First-line

Issue Date:

2019

Publisher:

Future Medicine Ltd

ISSN:

1479-6694

Note:

This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

Citation:

Corral-Jaime, J. (Jesús); Mok, T.S. (Tony S.); Nakagawa, K. (Kazuhiko); et al. "Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer". Future Oncology. 15 (24), 2019, 2795 - 2805

Abstract

Aim: We evaluated reasons for dacomitinib dose reduction (DR) and examined adverse event (AE) incidence, key efficacy end points (progression-free survival [PFS]/overall survival [OS]), and pharmacokinetics in dose-reducing patients in the ARCHER 1050 trial. Patients & methods: Newly diagnosed patients with EGFR mutation-positive, advanced non-small-cell lung cancer received oral dacomitinib (45 mg once-daily [QD]), with stepwise toxicity-managing DR (30 and 15 mg QD) permitted. Results: Skin toxicities (62.7%) were the most common DR-leading AEs. The AE incidence and severity decreased following DRs. Initial plasma dacomitinib exposure (45 mg QD) was generally lower in patients remaining at 45 mg QD compared with dose-reducing patients. Median PFS and OS were similar in all dacomitinib-treated patients and dose-reducing patients. Conclusion: Tolerability-guided dose modifications enabled patients to continue with dacomitinib and benefit from PFS/OS improvement.

URI:

https://hdl.handle.net/10171/62028

DOI:

10.2217/fon-2019-0299

Appears in Collections:

DA - CUN - Oncología médica - Artículos de revista

Files in This Item: